glp-1 drugs kidney disease Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney effects of Glucagon-Like Peptide
Description
To alleviate cardiac stress Black looked to blocking adrenalin, a chemical messenger that increases blood flow to muscles and in the process can overtax vulnerable hearts
The addition of GIP agonism in tirzepatide enhances first- and second-phase insulin secretion, reduces fasting and postprandial glucagon concentrations and therefore reduces postprandial glucose levels further
In clinical trials, the results are modest but real
And weeks 36 through 48 approached a plateau in most participants, with weight either stabilizing or declining very slowly
